HEART score for acute chest pain is a clinical decision-making tool designed to stratify patients presenting to the emergency department with acute chest pain according to their short-term risk of major adverse cardiovascular events (MACE), defined as all-cause mortality, myocardial infarction, or urgent coronary revascularization within 30 days4,6. Developed to overcome the limitations of overly sensitive but less specific traditional scoring systems, the HEART score integrates five key historical and clinical variables: History, Electrocardiogram (ECG), Age, Risk factors for coronary artery disease, and Troponin levels4,6. By rapidly identifying patients at ultra-low risk who can be safely discharged and isolating high-risk individuals requiring urgent invasive management, the HEART score optimizes resource utilization and reduces overcrowding in emergency departments while maintaining high diagnostic accuracy for acute coronary syndrome (ACS)2,5.

Etiology & Risk Factors

  • Underlying Coronary Artery Disease (CAD): Atherosclerotic plaque disruption, plaque rupture, or endothelial erosion leading to coronary thrombosis and myocardial ischemia1,2.
  • Demand Ischemia (Type 2 ACS): Tachyarrhythmias, severe hypertension, hypotension, anemia, or respiratory failure increasing myocardial oxygen demand in the presence of fixed coronary stenoses3.
  • Non-Coronary Life-Threatening Causes of Chest Pain: Acute aortic dissection, pulmonary embolism, tension pneumothorax, and esophageal rupture, all of which must be actively excluded during emergency evaluation2,5.
  • Established Cardiovascular Risk Factors: Age over 45 years in men or 55 years in women, systemic arterial hypertension, dyslipidemia, diabetes mellitus, cigarette smoking, and a positive family history of premature coronary artery disease4.

Pathophysiology

Acute chest pain suggestive of cardiac ischemia typically stems from an imbalance between myocardial oxygen supply and demand. Atherosclerotic plaque destabilization triggers platelet adhesion, activation, and aggregation, followed by activation of the coagulation cascade and partial or complete luminal obstruction of an epicardial coronary artery. Prolonged ischemia leads to rapid cellular adenosine triphosphate (ATP) depletion, anaerobic glycolysis, intracellular calcium overload, and loss of membrane integrity, culminating in reversible stunning or irreversible myocardial necrosis. Myocardial necrosis causes the intracellular release of structural proteins, most notably cardiac troponins I and T, into the microvasculature and cardiac interstitium, which subsequently enter the systemic circulation and serve as primary biochemical markers of cellular injury1,2. The HEART score evaluates the clinical probability of this exact pathophysiological cascade by quantifying symptom characteristics, electrical manifestations on the surface ECG, patient age, baseline atherosclerotic burden, and circulating biomarker levels4,6.

HEART score for acute chest pain — Pathophysiological Cascade & Clinical Flowchart 1 Patient Presentation Emergency department admission for undifferentiated acute chest pain and suspected myocardial ischemia. 2 Risk Component Evaluation Clinical scoring across five domains: History, Electrocardiogram (ECG), Age, Risk factors, and Troponin. 3 Score Summation & Stratification Aggregation yielding a total score from 0 to 10 to establish 30-day MACE risk probability. 4 Triage & Diagnostic Action Rapid discharge for low-risk scores (0–3) versus intensive monitoring and early invasive angiography for high-risk scores (7–10). 5 Therapeutic Intervention Prevention of myocardial necrosis and adverse cardiovascular events via antiplatelet, anticoagulant, and revascularization protocols.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Retrosternal pressure, tightness, squeezing, or heaviness radiating to the left arm, neck, jaw, or epigastrium. Classic ischemic symptoms are often precipitated by physical exertion or emotional stress and relieved by rest or sublingual nitroglycerin1. Atypical presentations, including isolated dyspnea, diaphoresis, nausea, or lightheadedness, are frequently observed in female, elderly, and diabetic patients2.
  • Physical Examination & Named Clinical Signs: General appearance often reveals diaphoresis, pallor, or acute distress. Cardiovascular examination may detect a third heart sound (S3 gallop) indicating left ventricular systolic dysfunction, a new or transient mitral regurgitation murmur due to papillary muscle ischemia, or paradoxical splitting of the second heart sound. Levine sign (clenching a fist over the sternum) is a classic physical indicator of visceral cardiac pain1,2.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationCoronary computed tomography angiography (CCTA) demonstrating absence of obstructive coronary stenosis in low-to-intermediate risk cohorts, or invasive coronary angiography showing critical coronary luminal narrowing (>70% stenosis) in high-risk patients3,5.
Laboratory PanelSerial high-sensitivity cardiac troponin I or T assays demonstrating dynamic rise and/or fall patterns exceeding the 99th percentile upper reference limit. Complete blood count, baseline metabolic panel, and lipid profile to assess systemic comorbidities1,2.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography to rule out widened mediastinum (aortic dissection), pulmonary infiltrates, or congestive heart failure. Transthoracic echocardiography to identify regional wall motion abnormalities, left ventricular ejection fraction, and structural valvular disease2,5.
ECG / Histopathology / Procedural12-lead ECG obtained within 10 minutes of presentation showing ST-segment elevation (>1 mm in two contiguous leads), ST-segment depression, deep T-wave inversions (e.g., Wellens syndrome), or new left bundle branch block. Histopathology of infarcted myocardium reveals contraction band necrosis, neutrophilic infiltration, and subsequent coagulation necrosis1,4.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
History (H)Highly suspicious (classic symptoms) = 2 points; Moderately suspicious (slightly atypical) = 1 point; Asymptomatic or non-specific symptoms = 0 points4,6.
Electrocardiogram (E)Significant ST-segment depression or elevation = 2 points; Non-specific repolarization abnormalities or left bundle branch block = 1 point; Normal ECG = 0 points4,6.
Age (A)Age >= 65 years = 2 points; Age 45–65 years = 1 point; Age < 45 years = 0 points4,6.
Risk Factors (R)3 or more risk factors or documented history of atherosclerotic disease = 2 points; 1 or 2 risk factors = 1 point; No known risk factors = 0 points4,6.
Troponin (T)Elevated level >= 3x normal upper limit = 2 points; Elevated level 1–3x normal upper limit = 1 point; Normal troponin level = 0 points4,6.
Total Score & Clinical StratificationScore 0–3: Low risk (30-day MACE ~0.9–1.7%, eligible for early discharge); Score 4–6: Moderate risk (30-day MACE ~12–16%, requires observation/serial testing); Score 7–10: High risk (30-day MACE ~50–65%, requires urgent invasive evaluation)4,6.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Acute Aortic DissectionSudden onset "tearing" or "ripping" chest pain radiating to the back; pulse deficits or blood pressure differentials between limbs; widened mediastinum on chest radiography confirmed by CTA.
Pulmonary EmbolismPleuritic chest pain, acute dyspnea, tachycardia, risk factors for deep vein thrombosis; elevated D-dimer, right ventricular strain on echocardiography, and filling defects on pulmonary CTA.
Esophageal Spasm / GERDRetrograde burning or cramping pain mimicking angina; often triggered by swallowing or specific foods; lack of ischemic ECG changes and normal serial troponin levels.
Pericarditis / MyocarditisSharp, pleuritic chest pain relieved by sitting forward; diffuse concave ST-segment elevations and PR-segment depressions on ECG; elevated inflammatory markers (ESR, CRP).

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Continuous cardiac telemetry, pulse oximetry, and placement of large-bore intravenous access. Administer supplemental oxygen only if arterial oxygen saturation drops below 90%1,2.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): Administer chewable aspirin 162 mg to 325 mg immediately. Provide sublingual nitroglycerin 0.4 mg every 5 minutes for up to 3 consecutive doses for ongoing ischemic discomfort, provided systolic blood pressure remains above 90 mmHg. Initiate P2Y12 receptor inhibitors (e.g., clopidogrel 300 mg loading dose or ticagrelor 180 mg loading dose) and anticoagulation (e.g., unfractionated heparin 60 units/kg IV bolus followed by 12 units/kg/h infusion) for patients stratified into intermediate-to-high risk categories with suspected ACS1,2.
  • Surgical / Interventional Indications: Urgent diagnostic coronary angiography and primary percutaneous coronary intervention (PCI) within 120 minutes of first medical contact for ST-elevation myocardial infarction (STEMI) or high-risk non-ST-elevation ACS (NSTE-ACS) with hemodynamic instability, refractory chest pain, or malignant arrhythmias2,5.

Complications & Prognosis

  • Key acute complications include cardiogenic shock, acute decompensated heart failure, malignant ventricular arrhythmias (ventricular fibrillation or pulseless ventricular tachycardia), mechanical complications (papillary muscle rupture, ventricular septal defect, free wall rupture), and acute thromboembolic stroke1,4.
  • Long-term prognosis is directly correlated with baseline risk stratification scores, baseline left ventricular ejection fraction, extent of coronary artery disease, and timely execution of coronary revascularization. Low HEART scores (0–3) confer an exceptionally low short-term mortality and MACE rate, whereas high scores demand intensive inpatient management to mitigate significant 30-day morbidity and mortality4,6.